Subcutaneous Rituximab with Recombinant Human Hyaluronidase in the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

References

• Coiffier B , LepageE, BriereJet al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Coiffier B , ThieblemontC, Van Den NesteEet al. Long-term outcome of patients in the LNH-98. 5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood116(12), 2040–2045 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization . WHO model list of essential medicines (19th Edition) (2015). www.who.int/medicines/publications/essentialmedicines/en/.
   Google Scholar
• Eichhorst B , RobakT, MontserratEet al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v78–v84 (2015).
   PubMed Web of Science ®Google Scholar
• Tilly H , Gomes da SilvaM, VitoloUet al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v116–v125 (2015).
   PubMed Web of Science ®Google Scholar
• Dreyling M , GhielminiM, RuleSet al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27(Suppl. 5), v83–v90 (2016).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Summary of product characteristics – rituximab. 14–16 (2000). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
   Google Scholar
• Reff ME , CarnerK, ChambersKSet al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83(2), 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Weiner GJ . Rituximab: mechanism of action. Semin. Haematol.47(2), 115–123 (2011).
   Web of Science ®Google Scholar
• Chow KU , SommerladWD, BoehrerSet al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica87(1), 33–43 (2002).
   PubMed Web of Science ®Google Scholar
• Dakhil S , HermannR, SchreederMTet al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leuk. Lymphoma55(10), 2335–2340 (2014).
   PubMed Web of Science ®Google Scholar
• Rule S , CollinsGP, SamantaK. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J. Med. Econ.17(7), 459–468 (2014).
   PubMedGoogle Scholar
• Ponzetti C , CancianiM, FarinaM, EraS, WalzerS. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clin. Outcomes Res.8, 227–233 (2016).
   PubMed Web of Science ®Google Scholar
• Wynne C , HarveyV, SchwabeC, WaakaD, McIntyreC, BittnerB. Comparison of subcutaneous and intravenous administration of trastuzumab: a Phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J. Clin. Pharmacol.53(2), 192–201 (2013).
   PubMed Web of Science ®Google Scholar
• Jackisch C , KimSB, SemiglazovVet al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the Phase III HannaH study. Ann. Oncol.26(2), 320–325 (2015).
   PubMed Web of Science ®Google Scholar
• Shpilberg O , JackischC. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br. J. Cancer109(6), 1556–1561 (2013).
   PubMed Web of Science ®Google Scholar
• Pivot X , GligorovJ, MüllerVet al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol.14(10), 962–970 (2013).
   PubMed Web of Science ®Google Scholar
• Bookbinder LH , HoferA, HallerMFet al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release114(2), 230–241 (2006).
   PubMed Web of Science ®Google Scholar
• Wasserman RL , MelamedI, SteinMRet al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol.130(4), 951.e11–957.e11 (2012).
   Web of Science ®Google Scholar
• Frost GI . Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv.4(4), 427–440 (2007).
   PubMed Web of Science ®Google Scholar
• Wasserman RL , MelamedI, SteinMRet al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J. Clin. Immunol.36(6), 571–582 (2016).
   PubMed Web of Science ®Google Scholar
• Yocum RC , KennardD, HeinerLS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J. Infus. Nurs.30(5), 293–299 (2007).
   PubMedGoogle Scholar
• Tobinai K , IgarashiT, ItohKet al. Japanese multicenter Phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann. Oncol.15(5), 821–830 (2004).
   PubMed Web of Science ®Google Scholar
• Jäger U , FridrikM, ZeitlingerMet al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica97(9), 1431–1438 (2012).
   PubMed Web of Science ®Google Scholar
• Wang DD , ZhangS, ZhaoH, MenAY, ParivarK. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J. Clin. Pharmacol.49(9), 1012–1024 (2009).
   PubMed Web of Science ®Google Scholar
• Bittner B , RichterWF, HertingFet al. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res. (Stuttg)64(11), 569–575 (2014).
   PubMedGoogle Scholar
• Mao CP , BrovarneyMR, DabbaghK, BirnböckHF, RichterWF, Del NagroCJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS ONE8(11), 1–12 (2013).
   Web of Science ®Google Scholar
• Salar A , AviviI, BittnerBet al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, Phase IB study. J. Clin. Oncol.32(17), 1782–1791 (2014).
   PubMed Web of Science ®Google Scholar
• Davies A , MerliF, MihaljevicBet al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised Phase III study. Lancet Oncol.15(14), 343–352 (2014).
   PubMedGoogle Scholar
• Davies A , MerliF, MihaljevićBet al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, Phase III trial. Lancet Haematol.4(6), e272–e282 (2017).
   PubMed Web of Science ®Google Scholar
• Assouline S , BuccheriV, DelmerAet al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br. J. Clin. Pharmacol.80(5), 1001–1009 (2015).
   PubMed Web of Science ®Google Scholar
• Assouline S , BuccheriV, DelmerAet al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a Phase IB, open-label, randomised controlled non-inferiority trial. Lancet Haematol.3(3), e128–e138 (2016).
   PubMed Web of Science ®Google Scholar
• Lugtenburg P , AviviI, BerenschotHet al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica102(11), 1913–1922 (2017).
   PubMed Web of Science ®Google Scholar
• Rummel M , KimTM, AversaFet al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann. Oncol.28(4), 836–842 (2016).
   Web of Science ®Google Scholar
• US FDA . FDA approves rituximab plus hyaluronidase combination for treatment of FL, DLBCL and CLL (2017). www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm.
   Google Scholar
• Rule S , BrionesJ, SmithRet al. Preference for rituximab subcutaneous (SC) and intravenous (IV) among patients with CD20+ non-Hodgkin’s lymphoma (NHL) completing the RASQ measure in randomized Phase III studies prefmab and mabcute. Value Health17(7), A537 (2014).
   PubMed Web of Science ®Google Scholar
• De Cock E , KritikouP, SandovalMet al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE11(6), e0157957 (2016).
   PubMed Web of Science ®Google Scholar